share_log

Biodexa Pharmaceuticals | 6-K: Report of foreign private issuer [Rules 13a-16 and 15d-16]

SEC announcement ·  May 21 10:54
Summary by Moomoo AI
Biodexa Pharmaceuticals PLC, a clinical stage biopharmaceutical company, announced positive results from a Phase 2 clinical trial of its drug eRapa in treating Familial Adenomatous Polyposis (FAP). The trial, which was partially funded by a $20 million grant from the Cancer Prevention and Research Institute of Texas, showed an 83% non-progression rate and a statistically significant decrease in overall mean polyp burden at 6 months. The results are scheduled for presentation at the 2024 Digestive Disease Week annual meeting in Washington D.C. The open-label study involved 30 adult patients across seven U.S. centers, with three different dosing cohorts over a 12-month treatment period. The primary endpoints were safety, tolerability, and percentage change from baseline in polyp burden at six months. The drug...Show More
Biodexa Pharmaceuticals PLC, a clinical stage biopharmaceutical company, announced positive results from a Phase 2 clinical trial of its drug eRapa in treating Familial Adenomatous Polyposis (FAP). The trial, which was partially funded by a $20 million grant from the Cancer Prevention and Research Institute of Texas, showed an 83% non-progression rate and a statistically significant decrease in overall mean polyp burden at 6 months. The results are scheduled for presentation at the 2024 Digestive Disease Week annual meeting in Washington D.C. The open-label study involved 30 adult patients across seven U.S. centers, with three different dosing cohorts over a 12-month treatment period. The primary endpoints were safety, tolerability, and percentage change from baseline in polyp burden at six months. The drug was well-tolerated with only two drug-related Grade 3 Serious Adverse Events reported, and 97% of patients remained on treatment at six months. eRapa, a proprietary oral tablet formulation of rapamycin, is designed to improve bioavailability and reduce toxicity. It has received Orphan Designation in the US, with plans to seek the same in Europe. Biodexa Pharmaceuticals, which focuses on developing treatments for diseases with unmet medical needs, also has other products in its pipeline, including treatments for Non Muscle Invasive Bladder Cancer, type 1 diabetes, and rare/orphan brain cancer indications. The company's R&D facility is based in Cardiff, UK.

This announcement is a separate document:

Doc 1

Doc 2

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more